Adverse events of immune checkpoint inhibitors in advanced hepatocellular carcinoma and their prognostic significance

Abstract

Asia-Pacific Journal of Clinical OncologyEarly View LETTER TO THE EDITOR Adverse events of immune checkpoint inhibitors in advanced hepatocellular carcinoma and their prognostic significance Markus Wilhelmi, Corresponding Author Markus Wilhelmi dr.markus.wilhelmi@gmail.com orcid.org/0000-0003-0121-0627 Medical Clinic I Gastroenterology and Hepatology, Nutritional Medicine, University Hospital, Frankfurt, Germany Correspondence Markus Wilhelmi, Medical Clinic I Gastroenterology and Hepatology, Nutritional Medicine, University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germania, Frankfurt, Germany. Email: dr.markus.wilhelmi@gmail.comSearch for more papers by this author Markus Wilhelmi, Corresponding Author Markus Wilhelmi dr.markus.wilhelmi@gmail.com orcid.org/0000-0003-0121-0627 Medical Clinic I Gastroenterology and Hepatology, Nutritional Medicine, University Hospital, Frankfurt, Germany Correspondence Markus Wilhelmi, Medical Clinic I Gastroenterology and Hepatology, Nutritional Medicine, University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germania, Frankfurt, Germany. Email: dr.markus.wilhelmi@gmail.comSearch for more papers by this author First published: 04 July 2021 https://doi.org/10.1111/ajco.13610Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinked InRedditWechat No abstract is available for this article. Early ViewOnline Version of Record before inclusion in an issue RelatedInformation